The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
24954801
DOI
10.1016/j.jtemb.2014.05.007
PII: S0946-672X(14)00073-X
Knihovny.cz E-zdroje
- Klíčová slova
- Chelating agents, Copper, Iron, Manganese, Parkinson's disease, Wilson's disease,
- MeSH
- hepatolentikulární degenerace metabolismus patofyziologie MeSH
- homeostáza MeSH
- lidé MeSH
- mangan metabolismus toxicita MeSH
- měď metabolismus toxicita MeSH
- modely nemocí na zvířatech MeSH
- mozek metabolismus patofyziologie MeSH
- Parkinsonova nemoc metabolismus patofyziologie MeSH
- vystavení vlivu životního prostředí škodlivé účinky MeSH
- železo metabolismus toxicita MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- mangan MeSH
- měď MeSH
- železo MeSH
Impaired cellular homeostasis of metals, particularly of Cu, Fe and Mn may trigger neurodegeneration through various mechanisms, notably induction of oxidative stress, promotion of α-synuclein aggregation and fibril formation, activation of microglial cells leading to inflammation and impaired production of metalloproteins. In this article we review available studies concerning Fe, Cu and Mn in Parkinson's disease and Wilson's disease. In Parkinson's disease local dysregulation of iron metabolism in the substantia nigra (SN) seems to be related to neurodegeneration with an increase in SN iron concentration, accompanied by decreased SN Cu and ceruloplasmin concentrations and increased free Cu concentrations and decreased ferroxidase activity in the cerebrospinal fluid. Available data in Wilson's disease suggest that substantial increases in CNS Cu concentrations persist for a long time during chelating treatment and that local accumulation of Fe in certain brain nuclei may occur during the course of the disease. Consequences for chelating treatment strategies are discussed.
2nd Department of Neurology Institute of Psychiatry and Neurology Warsaw Poland
Department of Chemistry Norwegian University of Science and Technology Trondheim Norway
Department of Medicine Innlandet Hospital Trust Kongsvinger Hospital Division Kongsvinger Norway
Citace poskytuje Crossref.org
